H.C. Wainwright assumed coverage of Ardelyx (ARDX) with a Buy rating and $10 price target The company has demonstrated approval and commercial execution with Ibsrela for the treatment of irritable bowel syndrome with constipation in adults and Xphozah for treating hyperphosphatemia, the analyst tells investors in a research note. The firm sees near-term commercial progress for Ardelyx.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx appoints Mike Kelliher Chief Business Officer
- Ardelyx presents data supporting IBSRELA at DDW 2025
- Ardelyx’s Strong Commercial Execution and Growth Prospects Support Buy Rating Despite Challenges
- Biotech Alert: Searches spiking for these stocks today
- Ardelyx Inc Reports Strong Growth Amid Challenges